Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
366
resultados
Última actualización
30/10/2026 [08:23:00]
Resultados 225 a 250 de 366
Resumen de: US20260276647A1
The present invention makes it possible to acquire biological information relating to an examination subject more easily or more accurately and to provide the biological information to a user. This living organism examination method for providing biological information relating to an examination subject (1), which is a living organism, by analyzing biological components in the sweat of the examination subject includes: a collection step (S101) for collecting sweat from an examination site of the examination subject (1); a measurement step (S102) for measuring a biological component profile of the sweat collected in the collection step; a biological information acquisition step (S103) for acquiring biological information relating to the examination subject (1) on the basis of the biological component profile measured in the measurement step; and an information provision step (S104) for providing the biological information relating to the examination subject, acquired in the biological information acquisition step, in a predetermined format.
Resumen de: US20260272867A1
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Resumen de: US20260276634A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: US20260272907A1
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
Resumen de: WO2025054130A1
The present disclosure relates to enzymes capable of oxidizing betahydroxybutyrate (BHB). In aspects, the enzymes are engineered to optimize BHB activity. Engineered enzymes including amino acid substitutions, truncations, and sequence deletions are further provided. The disclosure further provides for use of enzymes described herein, for example, in test strips, BHB sensors, devices, and systems for detecting and measuring BHB concentration.
Resumen de: US20260275418A1
A method is disclosed for detecting schizophrenia, at any stage, which comprises the steps of determining the gene expression of ZNF560 in a biological sample from a subject and comparing it with the ones of a healthy individual as a control sample, wherein the subject of the biological sample is diagnosed as having schizophrenia the gene ZNF560 is overexpressed in the biological sample in comparison to the control. Also disclosed is a kit of parts to diagnose schizophrenia from a biological sample and the use of the kit of parts as a detection agent useful to diagnose schizophrenia, wherein schizophrenia could be at prodromal, acute, residual, or chronic stage.
Resumen de: WO2026192282A1
An object of the present invention is to provide a method for recommending a treatment candidate group suitable for treatment with anti-amyloid antibody therapeutics by obtaining quantitative protein analysis data from blood and selecting a patient group at high risk of conversion to dementia.
Resumen de: WO2026192093A1
The present invention provides a digital olfactory data service platform comprising: a digital olfactory data collection system including a multi-channel olfactory sensor array provided to be able to collect digital olfactory data by using various types of odor collection samples collected in a plurality of fields, and a sensing management module provided to be able to manage the odor collection samples and the digital olfactory data; a digital olfactory AI data service system including a digital olfactory data lake, a digital olfactory data service management module, and a digital olfactory data management module, storing olfactory sample-related metadata, digital olfactory data, digital olfactory recognition data, and sensor management data, providing various data management functions stored in the digital olfactory data lake, and providing functions such as product management and subscription management for data services; and an olfactory recognition AI deep learning system including an olfactory recognition deep learning model for performing AI deep learning on the digital olfactory sensor data.
Resumen de: WO2026191421A1
Provided are a dementia diagnosis system and a dementia diagnosis program that are capable of identifying a patient having dementia with high accuracy by a simple and easy test. A dementia diagnosis system (1) has: a measurement unit (51) that continuously measures the acidity/basicity of a body fluid obtained from a subject; a confirmation unit (52) that confirms, for the acidity/basicity continuously measured by the measurement unit (51), an outlier at which the acidity/basicity becomes alkaline and the presence or absence of a change point at which the acidity/basicity persistently shifts to the alkaline side after the outlier is confirmed; and a prediction unit (53) that predicts whether or not the subject has dementia on the basis of the confirmation result of the confirmation unit (52).
Resumen de: WO2026193055A1
Described herein are humanized anti-ApoE antibody molecules, antigen-binding portions thereof, and uses thereof.
Resumen de: US20260276651A1
0000 The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject.
Resumen de: WO2026190495A1
The present invention refers to the field of in-vitro neural network stimulation, and particularly to devices that utilize cell cultures on multi-electrode arrays (MEAs) for investigating neuronal activity in research and drug testing applications. The invention consists of a closed loop system wherein a computational model stimulates via the electrodes of a MEA, cultured neurons on top of the MEA in order to produce disease- like activity states. The produced activity feeds back to the computational model, in real or periodic time, producing a hybrid neuronal population that can be used for drug screening. The respective method for the application of the abovementioned system is also disclosed.
Resumen de: WO2026190230A1
The present invention relates to alpha-synuclein antibodies which are useful in diagnostic assays for detecting aggregates, oligomers and fibrillar forms of alpha- synuclein in patient samples. These antibodies enable diagnosis and efficient treatment of alpha-synucleinopathies such as Parkinson's Disease (PD) or Multiple System Atrophy (MSA) patients by assessing and monitoring the pathological alpha-synuclein levels in patients.
Resumen de: WO2026193412A1
Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.
Resumen de: WO2026193026A1
The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).
Resumen de: WO2026193298A1
Described herein is a method of diagnosing or predicting the risk of cognitive decline in a subject, and/or stratifying the subject according to the risk. The method comprises determining a profile of the subject; and predicting the risk based on the profile, or stratifying the subject to a high risk group or a low risk group based on the predicted risk. The profile comprises blood pressure; and the level of homocysteine (Hyc) in a biological sample from the subject. Also described herein is a method of treating, ameliorating, and/or preventing cognitive decline in the subject based on the prediction of the risk.
Resumen de: WO2026189109A1
A high-sensitivity immunoassay method and system. The high-sensitivity immunoassay method for a target protein comprises: capturing the target protein to obtain a solution containing an immune complex; spreading said solution on a detection substrate under the action of a passive driving mechanism; immobilizing the immune complex on at least one surface; and performing detection and calculating the concentration of the immune complex. The immunoassay method uses a consumable structure having a simple structure and low costs, achieving highly sensitive detection of a target protein to be tested.
Resumen de: US20260273141A1
Disclosed herein are methods of inhibiting sterile alpha and TIR motif-containing protein 1 (SARM1) NADase activity in an axon. The methods can also be used to reduce or delay degeneration in an axon, treat or prevent degeneration of an injured axon, enhance fusion of one or more severed axons, and delay degeneration of one or more fused axons, as well as treat a neurological nerve injury or a neurodegenerative disease in a subject in need thereof using a SARM 1 inhibitor.
Resumen de: US20260276627A1
0000 Provided is a method for inhibiting macrophage neurotoxicity, the method comprising increasing expression of Aurora kinase in macrophages, wherein the Aurora kinase includes AURKA, AURKB, or a combination thereof. The expression may be increased by co-culturing the macrophages with neurons such as dorsal root ganglion sensory neurons, hippocampal neurons, dopaminergic neurons, motor neurons, cerebellar granule cells, thalamic neurons, or spinal cord neurons.
Resumen de: US20260276656A1
The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.
Resumen de: EP4807366A2
0001 The present disclosure relates to methods, systems, and devices for performing analyses of biological nanoparticles. More specifically, the present disclosure relates to methods, systems, and devices for performing single biological nanoparticle size determination on a sample while the biological nanoparticle is in transit through a microfluidic chip. In other aspects, the present disclosure relates to methods, systems, and devices for selectively capturing biological nanoparticles on a coated planar surface, the capturing being facilitated by centrifugation.
Resumen de: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Resumen de: WO2025041169A1
The present invention provides a kit, a device and an in-vitro assay based on a nanozyme-based lateral flow assay utilizing para-phenylenediamine of optimal concentration 0.1mM to 10mM as a chromogenic substrate for catalytically active aptamer-conjugated gold-nanozyme, which enhances sensitivity. The chromogenic substrate produces a robust brown color upon oxidation by catalytically active nanomaterial. The brown color remains stable for weeks and presents high contrast against the background. This overcomes the limitations of ordinary LFA in detecting analytes present at critical levels that are below microgram per milliliter, often resulting in false negative results. This provides a versatile and high-sensitive point-of-care diagnostic technique for rapid screening of infectious disease antigens and the detection of biomarkers for diseases such as cancer, cardiac and neurodegenerative diseases.
Resumen de: WO2025049921A1
The present disclosure provides a near full-length long read AIRR-seq (FLAIRR-Seq) method that utilizes targeted amplification by 5' rapid amplification of cDNA ends (RACE), combined with single molecule, real-time sequencing to generate highly accurate immunoglobulin (Ig) heavy chain and light chain transcripts.
Nº publicación: JP2026146131A 15/09/2026
Solicitante:
ザブリガムアンドウィメンズホスピタルインコーポレイテッド
Resumen de: WO2021262706A1
Provided herein are assays that provide digital measurement methods to detect proteins and other biomolecules, e.g., at low- to mid-attomolar concentrations.
BOPI
Sede Electrónica
